Human Growth Hormones Market By Application (Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small For Gestational Age, Prader-Willi Syndrome, And Others), Patient Type (Pediatric And Adults), Dosage (Injections, Capsules, And Powder), Route Of Administration (Subcutaneous, Oral, Intravenous, And Others), Distribution Channel (Hospital Pharmacy, Hypermarkets/Supermarkets, And E-Commerce), And Geography (North America, Europe, Asia-Pacific, And Rest Of The World) are expected to grow at a steady cagr forecast till 2030 owing to the increasing incidence of growth hormone deficiency, increased adoption of recombinant human human growth hormones, and increasing number of product approvals across the globe.
The global human growth hormones market was valued at USD 5.66 billion in 2023, growing at a CAGR of 8.74% during the forecast period from 2024 to 2030 to reach USD 10.14 billion by 2030. The demand for human growth hormones is primarily being boosted by the growing incidence of growth hormone deficiency in adults and pediatrics due to several reasons such as pituitary disorders, brain injuries, and parental & perinatal factors. Furthermore, the human growth hormones market is anticipated to grow on account of a large number of product approvals and increased adoption of recombinant human growth hormones across the globe. Hence, the above-mentioned factors are the major drivers that are responsible for contributing to the positive growth of the human growth hormones market during the forecast period from 2024 to 2030.
Additionally, as per the recent facts provided by Johns Hopkins University, about 1 in 10 people will develop a pituitary adenoma in their lifetime in the US. Endocrine-active pituitary tumors are responsible for causing hormonal imbalances that affect body functions. Additionally, pituitary tumors and pituitary adenoma can damage the hypothalamus or pituitary gland, leading to adult-onset growth hormone deficiency. Therefore, the increasing prevalence of pituitary tumors and pituitary adenoma, will escalate the demand for human growth hormones, thus driving the market for human growth hormones during the forecast period.
Parental and perinatal factors can negatively impact on fetal growth hormone deficiency such as preterm birth, low birth weight, and small-for-gestational-age (SGA) status. These factors can further contribute to the risk of growth hormone deficiency. As per the latest facts provided by UNICEF (2023), maternal undernutrition and anemia contribute to the high prevalence of low birth weight, affecting around 20 million infants globally, every year. Moreover, half of the 51 million children under the age of two suffer from stunted growth during pregnancy and the first six months of their life. This critical period underscores the dependency of children on growth hormones thereby boosting the market of human growth hormones.
Moreover, another key factor which is responsible for the market growth of human growth hormones is increased product approvals. For instance, in April 2023, the US FDA approved the Sogroya® for the treatment of children living with growth hormone deficiency. Thus, the introduction of Sogroya® can stimulate further research and development, attract investment, and drive competition, ultimately fostering innovation and enhancing market growth.
However, the prolonged use of growth hormones can lead to health-related risk factors and stringent regulatory approvals requiring extensive clinical trials to demonstrate safety and efficacy may hinder the market demand for human growth hormones.
In the product segment of the human growth hormones market, the growth hormone deficiency application is estimated to have a significant revenue share in the human growth hormones market in 2023. This can be attributed to the increasing cases of growth hormone deficiency diseases across the globe. Growth hormone deficiency is one of the most common pituitary hormone deficiencies, affecting both pediatric and adult populations. Unlike some other hormone deficiencies that may be managed with short-term or intermittent therapy, GHD typically requires long-term, often lifelong treatment with growth hormone replacement therapy. This sustained treatment regimen results in continuous demand for growth hormone products, contributing to market growth over time. Thus, according to the above mentioned factors the growth hormone deficiency category will contribute for the significant revenue share in the growth hormone market.
Additionally, stunted growth is one of the major complication resulting from growth hormone deficiency, and can have severe long-term health implications, including delayed physical development and psychological effects. The medical necessity to address these issues drives the demand for growth hormone therapies to ensure children achieve normal growth patterns. According to the data provided by the World Health Organization (2024), in 2022, a global estimate indicated that 149 million children under the age of five were stunted (short for their age), while 45 million were wasted (thin for their height). Thus, the increasing prevalence of stunting, will help to propel the growth hormone deficiencies category, thus in return contributing to the growth hormone market.
Further, ongoing clinical studies focusing on growth hormone deficiency (GHD) will also play a crucial role in the revenue share of the growth hormone deficiency category. For instance, in October 2020, Pfizer Inc. and OPKO Health Inc. shared news that a big study called C0311002, which looked at a new treatment for kids with low-growth hormones, met its main goal. This study compared a once-weekly dose of somatrogon to GENOTROPIN® which is given every day. The results showed that the new treatment made life easier for kids and their families compared to the daily injection.
Thus, the above mentioned factors related to human growth hormone deficiency are playing the major role in boosting the revenue share for human growth hormone deficiency category, thus contributing in the overall market of human growth hormones.
According to recent data provided by the American Cancer Society (2022), approximately more than 10,000 pituitary tumors are diagnosed each year in the United States. Additionally, as per the same source 1 in 4 people may have pituitary adenoma in the United States. Thus, the increasing prevalence of pituitary tumors and pituitary adenoma, can escalate the demand for human growth hormones as they directly affects the function of hypothalamus and pituitary gland.
Furthermore, recent strategic initiatives and various product approvals of human growth hormones are also aiding in driving the market growth of human growth hormones in the region. For instance, in June 2023, Pfizer Inc. and OPKO Health Inc. received FDA approval for NGENLA (somatropin-gala), a weekly human growth hormone analog. It's for children aged three and above with growth failure due to insufficient natural growth hormone secretion. Thus, the increasing new product approvals in the region is driving the market growth of human growth hormones in the United States.
Thus, the above mentioned factors are promoting the positive growth of human growth hormones in the region.
This product will be delivered within 2 business days.
The global human growth hormones market was valued at USD 5.66 billion in 2023, growing at a CAGR of 8.74% during the forecast period from 2024 to 2030 to reach USD 10.14 billion by 2030. The demand for human growth hormones is primarily being boosted by the growing incidence of growth hormone deficiency in adults and pediatrics due to several reasons such as pituitary disorders, brain injuries, and parental & perinatal factors. Furthermore, the human growth hormones market is anticipated to grow on account of a large number of product approvals and increased adoption of recombinant human growth hormones across the globe. Hence, the above-mentioned factors are the major drivers that are responsible for contributing to the positive growth of the human growth hormones market during the forecast period from 2024 to 2030.
Human Growth Hormones Market Dynamics:
According to the recent data provided by the Cancer Research UK (2023), about 17% of 100 brain tumors are pituitary tumors in the UK.Additionally, as per the recent facts provided by Johns Hopkins University, about 1 in 10 people will develop a pituitary adenoma in their lifetime in the US. Endocrine-active pituitary tumors are responsible for causing hormonal imbalances that affect body functions. Additionally, pituitary tumors and pituitary adenoma can damage the hypothalamus or pituitary gland, leading to adult-onset growth hormone deficiency. Therefore, the increasing prevalence of pituitary tumors and pituitary adenoma, will escalate the demand for human growth hormones, thus driving the market for human growth hormones during the forecast period.
Parental and perinatal factors can negatively impact on fetal growth hormone deficiency such as preterm birth, low birth weight, and small-for-gestational-age (SGA) status. These factors can further contribute to the risk of growth hormone deficiency. As per the latest facts provided by UNICEF (2023), maternal undernutrition and anemia contribute to the high prevalence of low birth weight, affecting around 20 million infants globally, every year. Moreover, half of the 51 million children under the age of two suffer from stunted growth during pregnancy and the first six months of their life. This critical period underscores the dependency of children on growth hormones thereby boosting the market of human growth hormones.
Moreover, another key factor which is responsible for the market growth of human growth hormones is increased product approvals. For instance, in April 2023, the US FDA approved the Sogroya® for the treatment of children living with growth hormone deficiency. Thus, the introduction of Sogroya® can stimulate further research and development, attract investment, and drive competition, ultimately fostering innovation and enhancing market growth.
However, the prolonged use of growth hormones can lead to health-related risk factors and stringent regulatory approvals requiring extensive clinical trials to demonstrate safety and efficacy may hinder the market demand for human growth hormones.
Human Growth Hormones Market Segment Analysis:
Human Growth Hormones Market by Application (Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small for Gestational Age, Prader-Willi Syndrome, and Others), Patient Type (Pediatric and Adults), Dosage (Injections, Capsules, and Powder), Route of Administration (Subcutaneous, Oral, Intravenous, and Others), Distribution Channel (Hospital Pharmacy, Hypermarkets/Supermarkets, and E-Commerce), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).In the product segment of the human growth hormones market, the growth hormone deficiency application is estimated to have a significant revenue share in the human growth hormones market in 2023. This can be attributed to the increasing cases of growth hormone deficiency diseases across the globe. Growth hormone deficiency is one of the most common pituitary hormone deficiencies, affecting both pediatric and adult populations. Unlike some other hormone deficiencies that may be managed with short-term or intermittent therapy, GHD typically requires long-term, often lifelong treatment with growth hormone replacement therapy. This sustained treatment regimen results in continuous demand for growth hormone products, contributing to market growth over time. Thus, according to the above mentioned factors the growth hormone deficiency category will contribute for the significant revenue share in the growth hormone market.
Additionally, stunted growth is one of the major complication resulting from growth hormone deficiency, and can have severe long-term health implications, including delayed physical development and psychological effects. The medical necessity to address these issues drives the demand for growth hormone therapies to ensure children achieve normal growth patterns. According to the data provided by the World Health Organization (2024), in 2022, a global estimate indicated that 149 million children under the age of five were stunted (short for their age), while 45 million were wasted (thin for their height). Thus, the increasing prevalence of stunting, will help to propel the growth hormone deficiencies category, thus in return contributing to the growth hormone market.
Further, ongoing clinical studies focusing on growth hormone deficiency (GHD) will also play a crucial role in the revenue share of the growth hormone deficiency category. For instance, in October 2020, Pfizer Inc. and OPKO Health Inc. shared news that a big study called C0311002, which looked at a new treatment for kids with low-growth hormones, met its main goal. This study compared a once-weekly dose of somatrogon to GENOTROPIN® which is given every day. The results showed that the new treatment made life easier for kids and their families compared to the daily injection.
Thus, the above mentioned factors related to human growth hormone deficiency are playing the major role in boosting the revenue share for human growth hormone deficiency category, thus contributing in the overall market of human growth hormones.
North America Is Expected To Dominate The Overall Human Growth Hormones Market:
North America is expected to account for the highest proportion of the global human growth hormones market in 2023, out of all regions. This is due to the presence of a large patient pool suffering from disorders related to the pituitary gland, as the pituitary gland is responsible for secreting a variety of growth hormones that influence various physiological processes throughout the body. Furthermore, the market for human growth hormones is anticipated to grow due to the increasing prevalence of pituitary tumors in the United States. Additionally, the market is anticipated to grow due to an increased number of product launches and ongoing clinical trials in the region.According to recent data provided by the American Cancer Society (2022), approximately more than 10,000 pituitary tumors are diagnosed each year in the United States. Additionally, as per the same source 1 in 4 people may have pituitary adenoma in the United States. Thus, the increasing prevalence of pituitary tumors and pituitary adenoma, can escalate the demand for human growth hormones as they directly affects the function of hypothalamus and pituitary gland.
Furthermore, recent strategic initiatives and various product approvals of human growth hormones are also aiding in driving the market growth of human growth hormones in the region. For instance, in June 2023, Pfizer Inc. and OPKO Health Inc. received FDA approval for NGENLA (somatropin-gala), a weekly human growth hormone analog. It's for children aged three and above with growth failure due to insufficient natural growth hormone secretion. Thus, the increasing new product approvals in the region is driving the market growth of human growth hormones in the United States.
Thus, the above mentioned factors are promoting the positive growth of human growth hormones in the region.
Human Growth Hormones Market Key Players:
Some of the key market players operating in the human growth hormones include Novo Nordisk A/S, Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Changchun GeneScience Pharmaceutical Co., Ltd., FERRING PHARMACEUTICALS, AnkeBio Co. Ltd, EMD Serono Inc., F.Hoffmann-La Roche Ltd, Ferring BV, Sandoz International GmbH, LG Life Sciences, Aeterna Zentaris, Sinobioway Hygene Biomedicine Co. Ltd, GeneScience Pharmaceuticals Co. Ltd, Strongbridge Biopharma, Ipsen SA, AnkeBio Co., Ltd, and othersRecent Developmental Activities In The Human Growth Hormones Market:
- In December 2021, Pfizer Inc. shared that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended somatrogon, a once-weekly growth hormone, for approval to treat children and adolescents aged 3 years and older who have growth issues.
- In August 2021, Ascendis Pharma A/S revealed that SKYTROFA® (lonapegsomatropin-tcgd), the first weekly treatment for pediatric growth hormone deficiency, has gained approval from the U.S. Food and Drug Administration.
Key Takeaways From The Human Growth Hormones Market Report Study
- Market size analysis for current Human Growth Hormones Market size (2023), and market forecast for 6 years (2024 to 2030)
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
- Key companies dominating the global Human Growth Hormones market.
- Various opportunities available for the other competitors in the Human Growth Hormones Market space.
- What are the top-performing segments in 2023? How these segments will perform in 2030?
- Which are the top-performing regions and countries in the current Human Growth Hormones market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for Human Growth Hormones market growth in the coming future?
Target Audience Who Can Be Benefited From This Human Growth Hormones Market Report Study
- Human Growth Hormones product providers
- Research organizations and consulting companies
- Human Growth Hormone related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and Traders dealing in human Growth Hormones
- Various end-users who want to know more about the human Growth Hormones market and the latest technological developments in the human Growth Hormones Market.
Frequently Asked Questions For The Human Growth Hormones Market:
1. What are human growth hormones?
Human Growth Hormones, also known as somatotropin or human growth hormone (HGH), are naturally occurring substances produced by the pituitary gland in the brain. These hormones play a crucial role in regulating growth, metabolism, and body composition.2. What is the market for human growth hormones?
The global human growth hormones market was valued at USD 5.66 billion in 2023, growing at a CAGR of 8.74% during the forecast period from 2024 to 2030 to reach USD 10.14 billion by 2030.3. What are the drivers for the global human growth hormones market?
The demand for human growth hormones is primarily being boosted by the growing incidence of growth hormone deficiency in adults and paediatrics due to several risk factors such as pituitary disorders, brain injuries, and parental & perinatal factors. Furthermore, the human growth hormones market is anticipated to grow on account of a large number of product approvals and increased adoption of recombinant growth hormones across the globe. These are the major drivers that are responsible for contributing to the positive growth of the human growth hormones market during the forecast period from 2024 to 2030.4. Who are the key players operating in the global human growth hormones market?
Some of the key market players operating in the Human Growth Hormones included Novo Nordisk A/S, Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Changchun GeneScience Pharmaceutical Co., Ltd., FERRING PHARMACEUTICALS, AnkeBio Co. Ltd, EMD Serono Inc., F.Hoffmann-La Roche Ltd, Ferring BV, Sandoz International GmbH, LG Life Sciences, Aeterna Zentaris, Sinobioway Hygene Biomedicine Co. Ltd, GeneScience Pharmaceuticals Co. Ltd, Strongbridge Biopharma, Ipsen SA, AnkeBio Co., Ltd, and others5. Which region has the highest share in the global human growth hormones market?
North America is expected to account for the highest proportion of the global human growth hormones market in 2023, out of all regions. This is due to the presence of a large patient pool suffering from disorders related to the pituitary gland as the pituitary gland is responsible for secreting a variety of human growth hormones that influence various physiological processes throughout the body. Furthermore, the market for human growth hormones is anticipated to grow due to the increasing prevalence of pituitary tumours in the United States. Additionally, the market is anticipated to grow due to an increased number of product launches and ongoing clinical trials in the region.This product will be delivered within 2 business days.
Table of Contents
1. Human Growth Hormones Market Report Introduction
2. Human Growth Hormones Market Executive Summary
4. Regulatory Analysis
5. Human Growth Hormones Market Key Factors Analysis
6. Human Growth Hormones Market Porter’s Five Forces Analysis
7. Human Growth Hormones Market Assessment
8. Human Growth Hormones Market Company and Product Profiles
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Novo Nordisk A/S
- Pfizer Inc
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Changchun GeneScience Pharmaceutical Co., Ltd.
- FERRING PHARMACEUTICALS
- AnkeBio Co. Ltd
- EMD Serono Inc.
- F.Hoffmann-La Roche Ltd
- Ferring BV
- Sandoz International GmbH
- LG Life Sciences
- Aeterna Zentaris
- Sinobioway Hygene Biomedicine Co. Ltd
- GeneScience Pharmaceuticals Co. Ltd
- Strongbridge Biopharma
- Ipsen SA
- AnkeBio Co., Ltd
